These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12234987)

  • 1. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy.
    Gatenby RA; Gawlinski ET; Tangen CM; Flanigan RC; Crawford ED
    Cancer Res; 2002 Sep; 62(18):5218-22. PubMed ID: 12234987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Rabets JC; Kaouk J; Fergany A; Finelli A; Gill IS; Novick AC
    Urology; 2004 Nov; 64(5):930-4. PubMed ID: 15533480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of radical nephrectomy in metastatic renal cell carcinoma.
    Flanigan RC; Yonover PM
    Semin Urol Oncol; 2001 May; 19(2):98-102. PubMed ID: 11354539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Margulis V; Matin SF; Wood CG
    Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
    J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
    Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz BJ; Figlin RA; Belldegrun AS
    J Urol; 2003 Jun; 169(6):2076-83. PubMed ID: 12771723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Healy KA; Marshall FF; Ogan K
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA
    Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.
    Margulis V; Tamboli P; Matin SF; Meisner M; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1878-82. PubMed ID: 17868733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.
    Klatte T; Patard JJ; de Martino M; Bensalah K; Verhoest G; de la Taille A; Abbou CC; Allhoff EP; Carrieri G; Riggs SB; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    J Urol; 2008 May; 179(5):1719-26. PubMed ID: 18343437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: Morbidity and long-term survival.
    Goetzl MA; Goluboff ET; Murphy AM; Katz AE; Mansukhani M; Sawczuk IS; Olsson CA; Benson MC; McKiernan JM
    Urol Oncol; 2004; 22(3):182-7. PubMed ID: 15271312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.
    Zini L; Capitanio U; Perrotte P; Jeldres C; Shariat SF; Arjane P; Widmer H; Montorsi F; Patard JJ; Karakiewicz PI
    Urology; 2009 Feb; 73(2):342-6. PubMed ID: 19041122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debulking nephrectomy in metastatic renal cancer.
    Flanigan RC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6335S-41S. PubMed ID: 15448027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes following partial nephrectomy by tumor size.
    Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
    J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy.
    Russo P
    Nat Clin Pract Urol; 2004 Nov; 1(1):26-30. PubMed ID: 16474463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
    Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
    Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
    Blute ML; Itano NB; Cheville JC; Weaver AL; Lohse CM; Zincke H
    J Urol; 2003 Apr; 169(4):1276-81. PubMed ID: 12629342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.